Important Information for Investors: Securities Class Action Lawsuit Against Viatris Inc.
On April 11, 2025, Kahn Swick & Foti, LLC (“KSF”) and its partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notified the investing public that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS). The lawsuit alleges that Viatris and certain of its executives violated federal securities laws by making false and misleading statements to the investing public, particularly during the period from August 8, 2024 to February 26, 2025 (the “Class Period”).
Background
Viatris is a global healthcare company that provides branded and generic pharmaceuticals, as well as a range of healthcare services. The Company was formed following the merger of Mylan N.V. and Pfizer Inc.’s Upjohn business.
Alleged Misstatements
The complaint filed in this class action lawsuit alleges that Viatris and its executives made false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the complaint alleges that the defendants failed to disclose: (1) that the Company’s combination therapy, Heplisav-B, had lower sales due to pricing pressures and competition; (2) that the Company was experiencing challenges in its generic business, including regulatory issues and pricing pressures; and (3) that the Company’s financial results would be adversely impacted by these issues.
Impact on Investors
During the Class Period, Viatris’ stock price traded at inflated levels, reaching a high of $26.81 per share on October 26, 2024. However, on February 26, 2025, the Company announced its fourth-quarter and full-year 2024 financial results, which fell short of analysts’ expectations. Following this announcement, the Company’s stock price dropped significantly, closing at $19.23 per share on February 28, 2025.
Investors who purchased Viatris’ securities during the Class Period may be able to recover their losses by serving as lead plaintiff in this securities class action lawsuit. In order to be eligible to serve as lead plaintiff, investors must meet certain requirements and deadlines, including filing a motion with the court before the lead plaintiff deadline.
Impact on the World
The securities class action lawsuit against Viatris is significant because it highlights the importance of transparency and accuracy in corporate communications. When companies fail to disclose material information, investors may make decisions based on incomplete or inaccurate information. This can lead to market volatility and potential losses for investors.
Moreover, the lawsuit may send a message to other healthcare companies and their executives to prioritize transparency and accuracy in their disclosures. This can help to maintain investor confidence and trust in the healthcare industry as a whole.
Conclusion
If you purchased Viatris securities during the Class Period, you may be able to recover your losses by serving as lead plaintiff in this securities class action lawsuit. It is important to act quickly and consult with an experienced securities attorney to determine your eligibility and protect your rights as an investor. Meanwhile, the lawsuit serves as a reminder to all companies and their executives to prioritize transparency and accuracy in their communications with the investing public.
- Investors who purchased Viatris securities during the Class Period may be able to recover their losses by serving as lead plaintiff in this securities class action lawsuit.
- The lawsuit alleges that Viatris and its executives made false and misleading statements regarding the Company’s business, operations, and prospects.
- The impact of the alleged misstatements on Viatris’ stock price may have caused significant losses for investors.
- The lawsuit highlights the importance of transparency and accuracy in corporate communications to maintain investor confidence and trust.
